{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T20:32:26Z","timestamp":1754598746607},"reference-count":84,"publisher":"Bentham Science Publishers Ltd.","issue":"6","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>A steady increase in the prevalence of drug-resistant tuberculosis (DR-TB) has already\nbeen reported in Pakistan. In addition, DR-TB is gradually changing from one-drug resistance\nto multi-drug resistance, which is a serious challenge for tuberculosis treatment. This\nreview provides an overview of the anti-tuberculosis drugs and focuses on the molecular mechanisms\nof drug resistance in Mycobacterium tuberculosis, with the hope that it will contribute to\nthe study of drug resistance in response to the emergence of multidrug-resistant tuberculosis.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892010257816230920053547","type":"journal-article","created":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T16:40:26Z","timestamp":1697388026000},"page":"724-736","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How do Mutations of Mycobacterium Genes Cause Drug Resistance in\nTuberculosis?"],"prefix":"10.2174","volume":"25","author":[{"given":"Kaiying","family":"Hou","sequence":"first","affiliation":[{"name":"School of Life Sciences, Henan University, Kaifeng, 475004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riffat","family":"Jabeen","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Henan University, Kaifeng, 475004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Sun","sequence":"additional","affiliation":[{"name":"College of Chemistry and Chemical Engineering,\nHenan University, Kaifeng, 475004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianshe","family":"Wei","sequence":"additional","affiliation":[{"name":"School of Life Sciences, Henan University, Kaifeng, 475004, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","year":"2022","unstructured":"Global tuberculosis report World Health Organization Available From:  https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-20222022","journal-title":"Global tuberculosis report"},{"key":"ref=2","year":"2021","unstructured":"Global tuberculosis report World Health Organization Available From:  https:\/\/www.who.int\/publications-detail-redirect\/97892400370212021","journal-title":"Global tuberculosis report"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12929-020-00667-6","volume":"27","author":"Gopalaswamy R.","year":"2020","unstructured":"Gopalaswamy R.; Shanmugam S.; Mondal R.; Subbian S.; Of tuberculosis and non-tuberculous mycobacterial infections \u2013 a comparative analysis of epidemiology, diagnosis and treatment. J Biomed Sci  2020,27(1),74","journal-title":"J Biomed Sci"},{"key":"ref=4","first-page":"7","volume":"58","year":"2009","unstructured":"Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep Centers for Disease Control and Prevention (CDC) 2009,58(1),7-10","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/j.drudis.2018.04.001","volume":"23","author":"Wu M.L.","year":"2018","unstructured":"Wu M.L.; Aziz D.B.; Dartois V.; Dick T.; NTM drug discovery: Status, gaps and the way forward. Drug Discov Today  2018,23(8),1502-1519","journal-title":"Drug Discov Today"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/cid\/ciw778","volume":"64","author":"Lewinsohn D.M.","year":"2017","unstructured":"Lewinsohn D.M.; Leonard M.K.; LoBue P.A.; Cohn D.L.; Daley C.L.; Desmond E.; Keane J.; Lewinsohn D.A.; Loeffler A.M.; Mazurek G.H.; O\u2019Brien R.J.; Pai M.; Richeldi L.; Salfinger M.; Shinnick T.M.; Sterling T.R.; Warshauer D.M.; Woods G.L.; Official american thoracic society\/infectious diseases society of america\/centers for disease control and prevention clinical practice guidelines: Diagnosis of tuberculosis in adults and children. Clin Infect Dis  2017,64(2),111-115","journal-title":"Clin Infect Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S2213-2600(18)30057-2","volume":"6","author":"Floyd K.","year":"2018","unstructured":"Floyd K.; Glaziou P.; Zumla A.; Raviglione M.; The global tuberculosis epidemic and progress in care, prevention, and research: An overview in year 3 of the End TB era. Lancet Respir Med  2018,6(4),299-314","journal-title":"Lancet Respir Med"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrmicro2333","volume":"8","author":"Kohanski M.A.","year":"2010","unstructured":"Kohanski M.A.; Dwyer D.J.; Collins J.J.; How antibiotics kill bacteria: From targets to networks. Nat Rev Microbiol  2010,8(6),423-435","journal-title":"Nat Rev Microbiol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1128\/AAC.47.8.2442-2444.2003","volume":"47","author":"Cynamon M.H.","year":"2003","unstructured":"Cynamon M.H.; Sklaney M.; Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother  2003,47(8),2442-2444","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"Aldred K.J.","year":"2014","unstructured":"Aldred K.J.; Kerns R.J.; Osheroff N.; Mechanism of quinolone action and resistance. Biochemistry  2014,53(10),1565-1574","journal-title":"Biochemistry"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1086\/319370","volume":"32","author":"Hooper D.C.","year":"2001","unstructured":"Hooper D.C.; Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis  2001,32(Suppl. 1),S9-S15","journal-title":"Clin Infect Dis"},{"key":"ref=12","first-page":"1320","volume":"13","author":"Zhang Y.","year":"2009","unstructured":"Zhang Y.; Yew W.W.; Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis  2009,13(11),1320-1330","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1128\/JCM.39.6.2330-2334.2001","volume":"39","author":"Abbadi S.","year":"2001","unstructured":"Abbadi S.; Rashed H.G.; Morlock G.P.; Woodley C.L.; El Shanawy O.; Cooksey R.C.; Characterization of IS6110 restriction fragment length polymorphism patterns and mechanisms of antimicrobial resistance for multidrug-resistant isolates of Mycobacterium tuberculosis from a major reference hospital in Assiut, Egypt. J Clin Microbiol  2001,39(6),2330-2334","journal-title":"J Clin Microbiol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1590\/S1806-37132010000500016","volume":"36","author":"Arbex M.A.","year":"2010","unstructured":"Arbex M.A.; Varella M.C.; Siqueira H.R.; Mello F.A.; Antituberculosis drugs: Drug interactions, adverse effects, and use in special situations. Part 1: First-line drugs. J Bras Pneumol  2010,36(5),626-640","journal-title":"J Bras Pneumol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"S102","DOI":"10.1093\/cid\/civ609","volume":"61","author":"Schito M.","year":"2015","unstructured":"Schito M.; Migliori G.B.; Fletcher H.A.; McNerney R.; Centis R.; D\u2019Ambrosio L.; Bates M.; Kibiki G.; Kapata N.; Corrah T.; Bomanji J.; Vilaplana C.; Johnson D.; Mwaba P.; Maeurer M.; Zumla A.; Perspectives on advances in tuberculosis diagnostics, drugs, and vaccines. Clin Infect Dis  2015,61(61)(Suppl. 3),S102-S118","journal-title":"Clin Infect Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4051","DOI":"10.1128\/JB.186.13.4051-4055.2004","volume":"186","author":"Zimhony O.","year":"2004","unstructured":"Zimhony O.; Vilch\u00e8ze C.; Jacobs W.R.; Characterization of Mycobacterium smegmatis expressing the Mycobacterium tuberculosis fatty acid synthase I (fas1) gene. J Bacteriol  2004,186(13),4051-4055","journal-title":"J Bacteriol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1128\/AAC.02765-15","volume":"60","author":"Parvez M.M.","year":"2016","unstructured":"Parvez M.M.; Jung J.A.; Shin H.J.; Kim D.H.; Shin J.G.; Characterization of 22 antituberculosis drugs for inhibitory interaction potential on organic anionic transporter polypeptide (OATP)-mediated uptake. Antimicrob Agents Chemother  2016,60(5),3096-3105","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S1286-4579(00)00359-2","volume":"2","author":"Slayden R.A.","year":"2000","unstructured":"Slayden R.A.; Barry C.E.; The genetics and biochemistry of isoniazid resistance in Mycobacterium tuberculosis. Microbes Infect  2000,2(6),659-669","journal-title":"Microbes Infect"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00894-017-3290-3","volume":"23","author":"Pimentel A.L.","year":"2017","unstructured":"Pimentel A.L.; de Lima Scodro R.B.; Caleffi-Ferracioli K.R.; Siqueira V.L.D.; Campanerut-S\u00e1 P.A.Z.; Lopes L.D.G.; de Almeida A.L.; Cardoso R.F.; Seixas F.A.V.; Mutations in catalase-peroxidase KatG from isoniazid resistant Mycobacterium tuberculosis clinical isolates: Insights from molecular dynamics simulations. J Mol Model  2017,23(4),121","journal-title":"J Mol Model"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jmii.2013.08.018","volume":"48","author":"Tseng S.T.","year":"2015","unstructured":"Tseng S.T.; Tai C.H.; Li C.R.; Lin C.F.; Shi Z.Y.; The mutations of katG and inhA genes of isoniazid-resistant Mycobacterium tuberculosis isolates in Taiwan. J Microbiol Immunol Infect  2015,48(3),249-255","journal-title":"J Microbiol Immunol Infect"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1128\/AAC.33.9.1493","volume":"33","author":"Takayama K.","year":"1989","unstructured":"Takayama K.; Kilburn J.O.; Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother  1989,33(9),1493-1499","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1021\/pr4010579","volume":"13","author":"Halouska S.","year":"2014","unstructured":"Halouska S.; Fenton R.J.; Zinniel D.K.; Marshall D.D.; Barletta R.G.; Powers R.; Metabolomics analysis identifies d-Alanine-d-Alanine ligase as the primary lethal target of d-Cycloserine in mycobacteria. J Proteome Res  2014,13(2),1065-1076","journal-title":"J Proteome Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1128\/AAC.00628-11","volume":"55","author":"Akbergenov R.","year":"2011","unstructured":"Akbergenov R.; Shcherbakov D.; Matt T.; Duscha S.; Meyer M.; Wilson D.N.; B\u00f6ttger E.C.; Molecular basis for the selectivity of antituberculosis compounds capreomycin and viomycin. Antimicrob Agents Chemother  2011,55(10),4712-4717","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1128\/AAC.47.1.283-291.2003","volume":"47","author":"Feng Z.","year":"2003","unstructured":"Feng Z.; Barletta R.G.; Roles of Mycobacterium smegmatis D-alanine:D-alanine ligase and D-alanine racemase in the mechanisms of action of and resistance to the peptidoglycan inhibitor D-cycloserine. Antimicrob Agents Chemother  2003,47(1),283-291","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.5588\/ijtld.12.0863","volume":"17","author":"Hwang T.J.","year":"2013","unstructured":"Hwang T.J.; Wares D.F.; Jafarov A.; Jakubowiak W.; Nunn P.; Keshavjee S.; Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis [Review article]. Int J Tuberc Lung Dis  2013,17(10),1257-1266","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"9677","DOI":"10.1073\/pnas.97.17.9677","volume":"97","author":"DeBarber A.E.","year":"2000","unstructured":"DeBarber A.E.; Mdluli K.; Bosman M.; Bekker L.G.; Barry C.E.; III Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc Natl Acad Sci USA  2000,97(17),9677-9682","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1128\/AAC.47.12.3799-3805.2003","volume":"47","author":"Morlock G.P.","year":"2003","unstructured":"Morlock G.P.; Metchock B.; Sikes D.; Crawford J.T.; Cooksey R.C.; ethA, inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother  2003,47(12),3799-3805","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=28","first-page":"97","volume":"8","author":"Johnson R.","year":"2006","unstructured":"Johnson R.; Streicher E.M.; Louw G.E.; Warren R.M.; van Helden P.D.; Victor T.C.; Drug resistance in Mycobacterium tuberculosis. Curr Issues Mol Biol  2006,8(2),97-111","journal-title":"Curr Issues Mol Biol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1128\/AAC.01049-15","volume":"60","author":"Chien J.Y.","year":"2016","unstructured":"Chien J.Y.; Chiu W.Y.; Chien S.T.; Chiang C.J.; Yu C.J.; Hsueh P.R.; Mutations in gyrA and gyrB among Fluoroquinolone and Multidrug-Resistant Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother  2016,60(4),2090-2096","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1590\/S1413-86702012000200005","volume":"16","author":"Chen J.","year":"2012","unstructured":"Chen J.; Chen Z.; Li Y.; Xia W.; Chen X.; Chen T.; Zhou L.; Xu B.; Xu S.; Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis  2012,16(2),136-141","journal-title":"Braz J Infect Dis"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/jac\/dkq202","volume":"65","author":"Chang K.C.","year":"2010","unstructured":"Chang K.C.; Yew W.W.; Chan R.C.Y.; Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: A systematic review and meta-analysis. J Antimicrob Chemother  2010,65(8),1551-1561","journal-title":"J Antimicrob Chemother"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1473-3099(03)00671-6","volume":"3","author":"Ginsburg A.S.","year":"2003","unstructured":"Ginsburg A.S.; Grosset J.H.; Bishai W.R.; Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis  2003,3(7),432-442","journal-title":"Lancet Infect Dis"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1128\/AAC.00944-06","volume":"50","author":"Matrat S.","year":"2006","unstructured":"Matrat S.; Veziris N.; Mayer C.; Jarlier V.; Truffot-Pernot C.; Camuset J.; Bouvet E.; Cambau E.; Aubry A.; Functional analysis of DNA gyrase mutant enzymes carrying mutations at position 88 in the A subunit found in clinical strains of Mycobacterium tuberculosis resistant to fluoroquinolones. Antimicrob Agents Chemother  2006,50(12),4170-4173","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1128\/AAC.48.2.596-601.2004","volume":"48","author":"Cheng A.F.B.","year":"2004","unstructured":"Cheng A.F.B.; Yew W.W.; Chan E.W.C.; Chin M.L.; Hui M.M.M.; Chan R.C.Y.; Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother  2004,48(2),596-601","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1128\/AAC.00920-10","volume":"55","author":"Lau R.W.T.","year":"2011","unstructured":"Lau R.W.T.; Ho P.L.; Kao R.Y.T.; Yew W.W.; Lau T.C.K.; Cheng V.C.C.; Yuen K.Y.; Tsui S.K.W.; Chen X.; Yam W.C.; Molecular characterization of fluoroquinolone resistance in Mycobacterium tuberculosis: Functional analysis of gyrA mutation at position 74. Antimicrob Agents Chemother  2011,55(2),608-614","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1128\/AAC.02358-15","volume":"60","author":"Li Q.","year":"2016","unstructured":"Li Q.; Jiao W.; Yin Q.; Xu F.; Li J.; Sun L.; Xiao J.; Li Y.; Mokrousov I.; Huang H.; Shen A.; Compensatory mutations of rifampin resistance are associated with transmission of multidrug-resistant Mycobacterium tuberculosis beijing genotype strains in China. Antimicrob Agents Chemother  2016,60(5),2807-2812","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1128\/AAC.01541-12","volume":"57","author":"de Vos M.","year":"2013","unstructured":"de Vos M.; M\u00fcller B.; Borrell S.; Black P.A.; van Helden P.D.; Warren R.M.; Gagneux S.; Victor T.C.; Putative compensatory mutations in the rpoC gene of rifampin-resistant Mycobacterium tuberculosis are associated with ongoing transmission. Antimicrob Agents Chemother  2013,57(2),827-832","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1080\/22221751.2020.1785334","volume":"9","author":"Swain S.S.","year":"2020","unstructured":"Swain S.S.; Sharma D.; Hussain T.; Pati S.; Molecular mechanisms of underlying genetic factors and associated mutations for drug resistance in Mycobacterium tuberculosis. Emerg Microbes Infect  2020,9(1),1651-1663","journal-title":"Emerg Microbes Infect"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1128\/AAC.47.4.1241-1250.2003","volume":"47","author":"Ramaswamy S.V.","year":"2003","unstructured":"Ramaswamy S.V.; Reich R.; Dou S.J.; Jasperse L.; Pan X.; Wanger A.; Quitugua T.; Graviss E.A.; Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother  2003,47(4),1241-1250","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/35030019","volume":"407","author":"Carter A.P.","year":"2000","unstructured":"Carter A.P.; Clemons W.M.; Brodersen D.E.; Morgan-Warren R.J.; Wimberly B.T.; Ramakrishnan V.; Functional insights from the structure of the 30S ribosomal subunit and its interactions with antibiotics. Nature  2000,407(6802),340-348","journal-title":"Nature"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1586\/14787210.6.5.713","volume":"6","author":"Banerjee R.","year":"2008","unstructured":"Banerjee R.; Schecter G.F.; Flood J.; Porco T.C.; Extensively drug-resistant tuberculosis: New strains, new challenges. Expert Rev Anti Infect Ther  2008,6(5),713-724","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1111\/j.1365-2958.2006.05585.x","volume":"63","author":"Okamoto S.","year":"2007","unstructured":"Okamoto S.; Tamaru A.; Nakajima C.; Nishimura K.; Tanaka Y.; Tokuyama S.; Suzuki Y.; Ochi K.; Loss of a conserved 7\u2010methylguanosine modification in 16S rRNA confers low\u2010level streptomycin resistance in bacteria. Mol Microbiol  2007,63(4),1096-1106","journal-title":"Mol Microbiol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1128\/AAC.01570-07","volume":"52","author":"Spies F.S.","year":"2008","unstructured":"Spies F.S.; Almeida da Silva P.E.; Ribeiro M.O.; Rossetti M.L.; Zaha A.; Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism. Antimicrob Agents Chemother  2008,52(8),2947-2949","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijmyco.2015.09.001","volume":"5","author":"Kambli P.","year":"2016","unstructured":"Kambli P.; Ajbani K.; Nikam C.; Sadani M.; Shetty A.; Udwadia Z.; Georghiou S.B.; Rodwell T.C.; Catanzaro A.; Rodrigues C.; Correlating rrs and eis promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int J Mycobacteriol  2016,5(1),1-6","journal-title":"Int J Mycobacteriol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1128\/AAC.04438-14","volume":"59","author":"Reeves A.Z.","year":"2015","unstructured":"Reeves A.Z.; Campbell P.J.; Willby M.J.; Posey J.E.; Disparities in capreomycin resistance levels associated with the rrs A1401G mutation in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother  2015,59(1),444-449","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1128\/AAC.00851-09","volume":"53","author":"Jugheli L.","year":"2009","unstructured":"Jugheli L.; Bzekalava N.; de Rijk P.; Fissette K.; Portaels F.; Rigouts L.; High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother  2009,53(12),5064-5068","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1128\/AAC.49.8.3192-3197.2005","volume":"49","author":"Maus C.E.","year":"2005","unstructured":"Maus C.E.; Plikaytis B.B.; Shinnick T.M.; Molecular analysis of cross-resistance to capreomycin, kanamycin, amikacin, and viomycin in Mycobacterium tuberculosis. Antimicrob Agents Chemother  2005,49(8),3192-3197","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.0907925106","volume":"106","author":"Zaunbrecher M.A.","year":"2009","unstructured":"Zaunbrecher M.A.; Sikes R.D.; Metchock B.; Shinnick T.M.; Posey J.E.; Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA  2009,106(47),20004-20009","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.molcel.2006.05.044","volume":"23","author":"Johansen S.K.","year":"2006","unstructured":"Johansen S.K.; Maus C.E.; Plikaytis B.B.; Douthwaite S.; Capreomycin binds across the ribosomal subunit interface using tlyA-encoded 2\u2032-O-methylations in 16S and 23S rRNAs. Mol Cell  2006,23(2),173-182","journal-title":"Mol Cell"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/nsmb.1755","volume":"17","author":"Stanley R.E.","year":"2010","unstructured":"Stanley R.E.; Blaha G.; Grodzicki R.L.; Strickler M.D.; Steitz T.A.; The structures of the anti-tuberculosis antibiotics viomycin and capreomycin bound to the 70S ribosome. Nat Struct Mol Biol  2010,17(3),289-293","journal-title":"Nat Struct Mol Biol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1183\/09031936.00028708","volume":"31","author":"Migliori G.B.","year":"2008","unstructured":"Migliori G.B.; Lange C.; Centis R.; Sotgiu G.; M\u00fctterlein R.; Hoffmann H.; Kliiman K.; De Iaco G.; Lauria F.N.; Richardson M.D.; Spanevello A.; Cirillo D.M.; Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J  2008,31(6),1155-1159","journal-title":"Eur Respir J"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1128\/JCM.01476-09","volume":"48","author":"Via L.E.","year":"2010","unstructured":"Via L.E.; Cho S.N.; Hwang S.; Bang H.; Park S.K.; Kang H.S.; Jeon D.; Min S.Y.; Oh T.; Kim Y.; Kim Y.M.; Rajan V.; Wong S.Y.; Shamputa I.C.; Carroll M.; Goldfeder L.; Lee S.A.; Holland S.M.; Eum S.; Lee H.; Barry C.E.; Polymorphisms associated with resistance and cross-resistance to aminoglycosides and capreomycin in Mycobacterium tuberculosis isolates from South Korean Patients with drug-resistant tuberculosis. J Clin Microbiol  2010,48(2),402-411","journal-title":"J Clin Microbiol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.diagmicrobio.2016.05.010","volume":"85","author":"Malinga L.","year":"2016","unstructured":"Malinga L.; Brand J.; Olorunju S.; Stoltz A.; van der Walt M.; Molecular analysis of genetic mutations among cross-resistant second-line injectable drugs reveals a new resistant mutation in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis  2016,85(4),433-437","journal-title":"Diagn Microbiol Infect Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/nrmicro3155","volume":"12","author":"Wilson D.N.","year":"2014","unstructured":"Wilson D.N.; Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat Rev Microbiol  2014,12(1),35-48","journal-title":"Nat Rev Microbiol"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s11274-013-1256-x","volume":"29","author":"Jnawali H.N.","year":"2013","unstructured":"Jnawali H.N.; Yoo H.; Ryoo S.; Lee K.J.; Kim B.J.; Koh W.J.; Kim C.K.; Kim H.J.; Park Y.K.; Molecular genetics of Mycobacterium tuberculosis resistant to aminoglycosides and cyclic peptide capreomycin antibiotics in Korea. World J Microbiol Biotechnol  2013,29(6),975-982","journal-title":"World J Microbiol Biotechnol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.advms.2015.09.007","volume":"61","author":"Njire M.","year":"2016","unstructured":"Njire M.; Tan Y.; Mugweru J.; Wang C.; Guo J.; Yew W.; Tan S.; Zhang T.; Pyrazinamide resistance in Mycobacterium tuberculosis: Review and update. Adv Med Sci  2016,61(1),63-71","journal-title":"Adv Med Sci"},{"key":"ref=57","first-page":"6","volume":"7","author":"Zhang Y.","year":"2003","unstructured":"Zhang Y.; Mitchison D.; The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis  2003,7(1),6-21","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1128\/AAC.41.3.540","volume":"41","author":"Scorpio A.","year":"1997","unstructured":"Scorpio A.; Lindholm-Levy P.; Heifets L.; Gilman R.; Siddiqi S.; Cynamon M.; Zhang Y.; Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother  1997,41(3),540-543","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=59","first-page":"802","volume":"10","author":"Louw G.E.","year":"2006","unstructured":"Louw G.E.; Warren R.M.; Donald P.R.; Murray M.B.; Bosman M.; Van Helden P.D.; Young D.B.; Victor T.C.; Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int J Tuberc Lung Dis  2006,10(7),802-807","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1128\/AAC.44.3.528-532.2000","volume":"44","author":"Cheng S.J.","year":"2000","unstructured":"Cheng S.J.; Thibert L.; Sanchez T.; Heifets L.; Zhang Y.; pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: Spread of a monoresistant strain in Quebec, Canada. Antimicrob Agents Chemother  2000,44(3),528-532","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1099\/mic.0.X00002-0","volume":"158","author":"Fivian-Hughes AS","year":"2012","unstructured":"Fivian-Hughes AS; Houghton J; Davis EO; Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiol-Sgm  2012,158,1388","journal-title":"Microbiol-Sgm"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1365-2958.2004.04120.x","volume":"53","author":"Rengarajan J.","year":"2004","unstructured":"Rengarajan J.; Sassetti C.M.; Naroditskaya V.; Sloutsky A.; Bloom B.R.; Rubin E.J.; The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria. Mol Microbiol  2004,53(1),275-282","journal-title":"Mol Microbiol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1111\/j.1365-2672.2010.04840.x","volume":"109","author":"Leung K.L.","year":"2010","unstructured":"Leung K.L.; Yip C.W.; Yeung Y.L.; Wong K.L.; Chan W.Y.; Chan M.Y.; Kam K.M.; Usefulness of resistant gene markers for predicting treatment outcome on second-line anti-tuberculosis drugs. J Appl Microbiol  2010,109(6),2087-2094","journal-title":"J Appl Microbiol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"4955","DOI":"10.1128\/IAI.70.9.4955-4960.2002","volume":"70","author":"Pym A.S.","year":"2002","unstructured":"Pym A.S.; Saint-Joanis B.; Cole S.T.; Effect of katG mutations on the virulence of Mycobacterium tuberculosis and the implication for transmission in humans. Infect Immun  2002,70(9),4955-4960","journal-title":"Infect Immun"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1128\/AAC.45.7.2157-2159.2001","volume":"45","author":"Lee A.S.G.","year":"2001","unstructured":"Lee A.S.G.; Teo A.S.M.; Wong S.Y.; Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother  2001,45(7),2157-2159","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/JB.182.7.1802-1811.2000","volume":"182","author":"Alland D.","year":"2000","unstructured":"Alland D.; Steyn A.J.; Weisbrod T.; Aldrich K.; Jacobs W.R.; Characterization of the Mycobacterium tuberculosis iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition. J Bacteriol  2000,182(7),1802-1811","journal-title":"J Bacteriol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.meegid.2016.09.004","volume":"45","author":"Unissa A.N.","year":"2016","unstructured":"Unissa A.N.; Subbian S.; Hanna L.E.; Selvakumar N.; Overview on mechanisms of isoniazid action and resistance in Mycobacterium tuberculosis. Infect Genet Evol  2016,45,474-492","journal-title":"Infect Genet Evol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1128\/AAC.01357-08","volume":"53","author":"Starks A.M.","year":"2009","unstructured":"Starks A.M.; Gumusboga A.; Plikaytis B.B.; Shinnick T.M.; Posey J.E.; Mutations at embB codon 306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother  2009,53(3),1061-1066","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1128\/AAC.41.8.1677","volume":"41","author":"Sreevatsan S.","year":"1997","unstructured":"Sreevatsan S.; Stockbauer K.E.; Pan X.; Kreiswirth B.N.; Moghazeh S.L.; Jacobs W.R.; Telenti A.; Musser J.M.; Ethambutol resistance in Mycobacterium tuberculosis: Critical role of embB mutations. Antimicrob Agents Chemother  1997,41(8),1677-1681","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1128\/JCM.40.5.1617-1620.2002","volume":"40","author":"Mokrousov I.","year":"2002","unstructured":"Mokrousov I.; Narvskaya O.; Limeschenko E.; Otten T.; Vyshnevskiy B.; Detection of ethambutol-resistant Mycobacterium tuberculosis strains by multiplex allele-specific PCR assay targeting embB306 mutations. J Clin Microbiol  2002,40(5),1617-1620","journal-title":"J Clin Microbiol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3349\/ymj.2002.43.1.59","volume":"43","author":"Lee H.Y.","year":"2002","unstructured":"Lee H.Y.; Myoung H.J.; Bang H.E.; Bai G.H.; Kim S.J.; Kim J.D.; Cho S.N.; Mutations in the embB locus among Korean clinical isolates of Mycobacterium tuberculosis resistant to ethambutol. Yonsei Med J  2002,43(1),59-64","journal-title":"Yonsei Med J"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1183\/09031936.00073611","volume":"38","author":"Falzon D.","year":"2011","unstructured":"Falzon D.; Jaramillo E.; Sch\u00fcnemann H.J.; Arentz M.; Bauer M.; Bayona J.; Blanc L.; Caminero J.A.; Daley C.L.; Duncombe C.; Fitzpatrick C.; Gebhard A.; Getahun H.; Henkens M.; Holtz T.H.; Keravec J.; Keshavjee S.; Khan A.J.; Kulier R.; Leimane V.; Lienhardt C.; Lu C.; Mariandyshev A.; Migliori G.B.; Mirzayev F.; Mitnick C.D.; Nunn P.; Nwagboniwe G.; Oxlade O.; Palmero D.; Pavlinac P.; Quelapio M.I.; Raviglione M.C.; Rich M.L.; Royce S.; R\u00fcsch-Gerdes S.; Salakaia A.; Sarin R.; Sculier D.; Varaine F.; Vitoria M.; Walson J.L.; Wares F.; Weyer K.; White R.A.; Zignol M.; WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J  2011,38(3),516-528","journal-title":"Eur Respir J"},{"key":"ref=73","first-page":"829","volume":"10","author":"Caminero J.A.","year":"2006","unstructured":"Caminero J.A.; Treatment of multidrug-resistant tuberculosis: Evidence and controversies. Int J Tuberc Lung Dis  2006,10(8),829-837","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"e01575","DOI":"10.1128\/AAC.01575-17","volume":"61","author":"Nakatani Y","year":"2017","unstructured":"Nakatani Y; Opel-Reading HK; Merker M; Role of alanine racemase mutations in Mycobacterium tuberculosis d-cycloserine resistance. Antimicrob Agents Chemother  2017,61(12),e01575-e01517","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"e43467","DOI":"10.1371\/journal.pone.0043467","volume":"7","author":"Chen JM","year":"2012","unstructured":"Chen JM; Uplekar S; Gordon SV; A point mutation in cycA partially contributes to the D-cycloserine resistance trait of mycobacterium bovis BCG vaccine strains. Plos One  2012,7(8),e43467","journal-title":"Plos One"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/jac\/dkx316","volume":"72","author":"Chen J.","year":"2017","unstructured":"Chen J.; Zhang S.; Cui P.; Shi W.; Zhang W.; Zhang Y.; Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother  2017,72(12),3272-3276","journal-title":"J Antimicrob Chemother"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"129","DOI":"10.5588\/ijtld.12.0511","volume":"17","author":"Vadwai V.","year":"2013","unstructured":"Vadwai V.; Ajbani K.; Jose M.; Vineeth V.P.; Nikam C.; Deshmukh M.; Shetty A.; Soman R.; Rodrigues C.; Can inhA mutation predict ethionamide resistance? Int J Tuberc Lung Dis  2013,17(1),129-130","journal-title":"Int J Tuberc Lung Dis"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1128\/AAC.01030-10","volume":"55","author":"Brossier F.","year":"2011","unstructured":"Brossier F.; Veziris N.; Truffot-Pernot C.; Jarlier V.; Sougakoff W.; Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother  2011,55(1),355-360","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S1413-8670(11)70264-1","volume":"15","author":"Lakshmi R.","year":"2011","unstructured":"Lakshmi R.; Kumar V.; Baskaran M.; Sundar S.; Rahman F.; Selvakumar N.; Ramachandran R.; Pattern of ethionamide susceptibility and its association with isoniazid resistance among previously treated tuberculosis patients from India. Braz J Infect Dis  2011,15(6),619-620","journal-title":"Braz J Infect Dis"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1469-0691.2009.02838.x","volume":"16","author":"Boonaiam S.","year":"2010","unstructured":"Boonaiam S.; Chaiprasert A.; Prammananan T.; Leechawengwongs M.; Genotypic analysis of genes associated with isoniazid and ethionamide resistance in MDR-TB isolates from Thailand. Clin Microbiol Infect  2010,16(4),396-399","journal-title":"Clin Microbiol Infect"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1128\/JCM.00561-08","volume":"46","author":"Abe C.","year":"2008","unstructured":"Abe C.; Kobayashi I.; Mitarai S.; Wada M.; Kawabe Y.; Takashima T.; Suzuki K.; Sng L.H.; Wang S.; Htay H.H.; Ogata H.; Biological and molecular characteristics of Mycobacterium tuberculosis clinical isolates with low-level resistance to isoniazid in Japan. J Clin Microbiol  2008,46(7),2263-2268","journal-title":"J Clin Microbiol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1099\/jmm.0.46718-0","volume":"55","author":"Guo H.","year":"2006","unstructured":"Guo H.; Seet Q.; Denkin S.; Parsons L.; Zhang Y.; Molecular characterization of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis from the USA. J Med Microbiol  2006,55(11),1527-1531","journal-title":"J Med Microbiol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/j.1365-2958.2008.06365.x","volume":"69","author":"Vilch\u00e8ze C.","year":"2008","unstructured":"Vilch\u00e8ze C.; Av-Gay Y.; Attarian R.; Liu Z.; Hazb\u00f3n M.H.; Colangeli R.; Chen B.; Liu W.; Alland D.; Sacchettini J.C.; Jacobs W.R.; Mycothiol biosynthesis is essential for ethionamide susceptibility in Mycobacterium tuberculosis. Mol Microbiol  2008,69(5),1316-1329","journal-title":"Mol Microbiol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","volume":"75","author":"Kadura S.","year":"2020","unstructured":"Kadura S.; King N.; Nakhoul M.; Zhu H.; Theron G.; K\u00f6ser C.U.; Farhat M.; Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother  2020,75(8),2031-2043","journal-title":"J Antimicrob Chemother"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010257816230920053547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/221860\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010257816230920053547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T12:31:22Z","timestamp":1715085082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/221860\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":84,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010257816230920053547","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}